Evidence map›Paper›PMID 38545094›Full record

ArticleFrontiers in immunology2024

Enhanced T cell receptor specificity through framework engineering.

Aaron M Rosenberg, Cory M Ayres, Angélica V Medina-Cucurella, Timothy A Whitehead, Brian M Baker

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Bottom-up synthetic immunology.Nature nanotechnology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Aaron M RosenbergDepartment of Chemistry and Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, United States.
Cory M AyresDepartment of Chemistry and Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, United States.
Angélica V Medina-CucurellaDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, United States.
Timothy A WhiteheadDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, United States.
Brian M BakerDepartment of Chemistry and Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, United States.
University of Notre Dame · USUniversity of Colorado Boulder · US

Funding

Structural biophysics and molecular design in cellular immunityR35GM118166 · NIGMS · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2016 to 2025
$4.4M
The influence of evolutionary landscapes on protective antibody developmentR01AI141452 · NIAID · UNIVERSITY OF COLORADO · PI WHITEHEAD, TIMOTHY ANDREW · 2019 to 2023
$2.8M
NRSA Training CoreTL1TR002531 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI FOTI, DANIEL JUSTIN, HURLEY, THOMAS D. · 2018 to 2022
$2.5M
Plant Biotechnology for Health and SustainabilityT32GM110523 · NIGMS · MICHIGAN STATE UNIVERSITY · PI LAST, ROBERT LOUIS · 2014 to 2023
$2.2M
BIACORE T200 SPR FOR NOTRE DAME BIOPHYSICS INSTRUMENTATION CORE (BIC) FACILITYS10OD028553 · OD · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2020 to 2020
$343k
NCATS NIH HHS TL1 TR002531NIAID NIH HHS R01 AI141452NIGMS NIH HHS R35 GM118166NIGMS NIH HHS T32 GM110523NIH HHS S10 OD028553
6 · The paper itself

Abstract

Development of T cell receptors (TCRs) as immunotherapeutics is hindered by inherent TCR cross-reactivity. Engineering more specific TCRs has proven challenging, as unlike antibodies, improving TCR affinity does not usually improve specificity. Although various protein design approaches have been explored to surmount this, mutations in TCR binding interfaces risk broadening specificity or introducing new reactivities. Here we explored if TCR specificity could alternatively be tuned through framework mutations distant from the interface. Studying the 868 TCR specific for the HIV SL9 epitope presented by HLA-A2, we used deep mutational scanning to identify a framework mutation above the mobile CDR3β loop. This glycine to proline mutation had no discernable impact on binding affinity or functional avidity towards the SL9 epitope but weakened recognition of SL9 escape variants and led to fewer responses in a SL9-derived positional scanning library. In contrast, an interfacial mutation near the tip of CDR3α that also did not impact affinity or functional avidity towards SL9 weakened specificity. Simulations indicated that the specificity-enhancing mutation functions by reducing the range of loop motions, limiting the ability of the TCR to adjust to different ligands. Although our results are likely to be TCR dependent, using framework engineering to control TCR loop motions may be a viable strategy for improving the specificity of TCR-based immunotherapies.

Indexed as

Receptors, Antigen, T-CellEpitopesMutationProtein BindingT-Cell Antigen Receptor SpecificityEpitopesReceptors, Antigen, T-Cellframework regionsmolecular dynamicsprotein engineeringspecificityT cell receptor

Identifiers

PMID38545094
PMCPMC10967027
OpenAlexW4392714383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.